TradingHolo

The whole market. One view. Market data from our own platform. Not investment advice. Prices in listing currency with AED alongside; market cap in USD. Live = streaming now; Delayed 15 min where the exchange requires it; At close = last official close.

News Calendar Economy IPOs ETFs Account

⌂Home ◈Markets ▦Screener 📈Tools ◎Portfolio

Skip to content

DFM General5,851.39−0.27%FTSE ADX9,783.24−0.26%TASI10,123.62−0.65%QE Index8,632.66−0.01%S&P 5007,690.73+0.41%Nasdaq 10029,529.34+1.17%Nifty 5022,888.95−1.11%Sensex73,852.90−1.17%KSE-100165,966.09−0.27%DFM:EMIRATESNBDAED 31.50−0.25%ADX:IHCAED 352.00−0.17%SAU:2222SAR 25.80+0.00%DSMD:QNBKQAR 15.66+2.29%NAS:NVDA$217.09+1.38%NYSE:TSM$420.22+1.84%NSE:RELIANCE₹1,202.00−0.76%KAR:OGDCRs 299.47+0.12%Gold$4,135.60−0.13%Brent$109.39+0.16%BTC$81,642.47−0.24%ETH$2,395.06−0.42%DFM General5,851.39−0.27%FTSE ADX9,783.24−0.26%TASI10,123.62−0.65%QE Index8,632.66−0.01%S&P 5007,690.73+0.41%Nasdaq 10029,529.34+1.17%Nifty 5022,888.95−1.11%Sensex73,852.90−1.17%KSE-100165,966.09−0.27%DFM:EMIRATESNBDAED 31.50−0.25%ADX:IHCAED 352.00−0.17%SAU:2222SAR 25.80+0.00%DSMD:QNBKQAR 15.66+2.29%NAS:NVDA$217.09+1.38%NYSE:TSM$420.22+1.84%NSE:RELIANCE₹1,202.00−0.76%KAR:OGDCRs 299.47+0.12%Gold$4,135.60−0.13%Brent$109.39+0.16%BTC$81,642.47−0.24%ETH$2,395.06−0.42%

Stock markets

🇦🇪UAEDFM · ADX · DFM GeneralClosed 🇸🇦Saudi ArabiaTadawul · TASIClosed 🇶🇦QatarQSE · QE GeneralClosed 🇺🇸United StatesNasdaq · NYSE · S&P 500Closed 🇮🇳IndiaNSE · BSE · Nifty 50Closed 🇵🇰PakistanPSX · KSE-100Closed

Other assets

₿CryptoRanked by volume · 24/7 🥇Gold, FX & economyDubai gold, AED crosses, rates ◫ETFsIndex, sector and gold funds

Explore

▦Market mapEvery market as a heatmap 📅Calendar & IPOsEarnings, dividends, listings, releases ⌁Options flow · Ownership · PoliticsUS filings and tapes

⚲Stock screenerAll six markets, one row per company ★Ready-made screensStarting points with a point of view 📁My saved screensSaved rules with alerts on new matches ⇄CompareUp to five, side by side

📈ChartingDrawings, indicators, replay ▶Strategy MakerWrite a rule, test it on history ⇄CompareSide by side 🔔AlertsPrice, earnings, screens, strategies

⌕

Sign in Create account👤

Anavex Life Sciences Corp · Overview · TradingHolo

Markets › United States › NAS › AVXL

A

Anavex Life Sciences Corp

NAS:AVXLHealthcareCBOEFTSE:MRUTNASDAQ:NBI

$1.25−4.58%At closeAt close · Tue 20 Oct · ≈ AED 4.59 · Market cap — · Next earnings Mon 30 Nov

🔔 Alert▶ Test a strategy

Overview Chart Financials Valuation Forecasts Dividends Ownership Options Shorts News Profile

1D

−4.6%

1M

−48.3%

3M

−51.2%

6M

−65.8%

1Y

−86.1%

Why it's moving today

No company news in the last day; the move tracks its market and sector.

AVXL −4.58% today

✦ This week in three lines

No written digest yet for AVXL. The figures on this page are the source when one is written.

Financials

USD millions · annual5Y CAGR —

Valuation

P/E vs sector—

Price / Book vs sector—

Price / Sales vs sector—

Price / Free cash flow vs sector—

Forecasts

1 buy0 hold0 sell1 analysts

Average target$0.0000 −100.0%

Analysts0

EPS surprises, last 87 beats

Dividends

Anavex Life Sciences Corp has not paid a dividend in the last five years.

Latest news

All AVXL news →

SEAnavex Life Sciences gains IND clearance for blarcamesine in Fragile X syndrome

Seeking Alpha · 4 d ago

REAnavex Receives FDA Clearance Of Its Ind Application For Blarcamesine In Fragile X Syndrome

Reuters · 4 d ago

DOAnavex Life Sciences Gets FDA OK for Clinical Study of Genetic Disorder Treatment

Dow Jones Newswires · 4 d ago

Key facts

At close · Tue 20 Oct

Market cap (USD)—

P/E—

Dividend yield—

52-week range$1.14 – $9.50

Avg volume (20d)1,448,018

Shares outstanding92,696,800

Beta1.14

Short interest14.9% of float

Next earningsMon 30 Nov

Radar Score

—

Value—

Quality—

Momentum—

Income—

Peer percentile within United States Healthcare0–100 · null when more than one input is missing

About

Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both…

SectorHealthcare

IndustryNormal

ExchangeNAS

Peers

LLNYSE:LLYEli Lilly and Co · 🇺🇸 NYSE

57.3×−1.33%

JNNYSE:JNJJohnson & Johnson · 🇺🇸 NYSE

23.0×−0.69%

ABNYSE:ABBVAbbVie Inc · 🇺🇸 NYSE

119.3×−0.96%

UNNYSE:UNHUnitedHealth Group Inc · 🇺🇸 NYSE

29.9×+1.36%